Duodart 0,5 mg Capsules
PDF Leaflet Revision Date: 17 August 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH).
Dosage (summary)
One capsule orally daily, 30 minutes after the same meal.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in women; potential risk to male fetus.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP2D6 inhibitors
- Other alpha blockers
- PDE5 inhibitors
Contraindications
- Hypersensitivity to components
- Women and children
- Orthostatic hypotension
- Severe hepatic impairment
Common side effects
- Impotence
- Decreased libido
- Ejaculation disorders
- Breast disorders
- Dizziness
Counselling Points
- Take with water after the same meal daily
- Report breast changes
- Avoid contact with leaking capsules
- Monitor PSA levels regularly
Serious warnings
- Increased risk of prostate cancer
- Cardiac failure risk
- Orthostatic hypotension
- Intra-operative Floppy Iris Syndrome
Important Disclaimer
The Duodart 0,5 mg Capsules professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
